Mumbai, June 30 -- Shilpa Medicare announced that its wholly owned subsidiary, Shilpa Biologicals, has entered into a co development and supply agreement with Orion Corporation for intravenous(IV) nivolumab biosimilar referencing one of the world's most widely used cancer immunotherapies - bringing two companies together to widen patient access across Europe.

Published by HT Digital Content Services with permission from Capital Market....